Teva Acquires 51 Percent Of Immuneering Corp.

August 5, 2015 | Teva Pharmaceutical Industries announced that it would acquire 51 percent of Immuneering Corp. for an undisclosed amount. Immuneering Corp is a genomic analysis company based out of Cambridge, Massachusetts using breakthrough technology to discover hidden signs and gain biological insights from genetic, genomic and proteomic data. Teva and Immuneering have worked together in the past several years to make progress in research on biomarkers, gene expression signatures and other cutting-edge diagnostic tools. Teva was founded in 1901 by Chaim Salomon, Moshe Levin and Yitschak Elstein.